-
Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform
•
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health…
-
JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products
•
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series B financing rounds, raising a total of RMB 700 million (USD 102.5 million). Investors include SinoRock, Guanghua Wutong Equity Investment Fund, YuanHengLiZhen, Weigao Holding, and HM Capital. The funding follows a Series A round led…
-
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million (USD 14.6 million) in a Series C+ financing round. The funding was backed by Guoyao Zhongjin (Shanghai) Medical Health Investment, ZhangKeHeRun Fund, Lingang Lanwan Private Equity Fund, and SPINNOTEC/Haiwang Capital. With this latest round, ZhenGe…
-
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
•
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi in a Series A+ financing round led by existing investors. The funds will be used to accelerate a Phase I clinical study and pre-clinical research, expand the product pipeline, and enhance the technology platform. Company…
-
mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC
•
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an undisclosed amount of money in a Series B1 financing round. The round was solely led by AstraZeneca and CICC’s first joint global medical fund. Proceeds will be used to expand its product pipeline for women’s…
-
Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion
•
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization (CDMO) with a business unit in Shanghai, has reportedly raised close to RMB 250 million (USD 36.7 million) in a Series B financing round. The round was led by Shanghai Biomedicine Fund and included contributions…
-
Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
•
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public offering (IPO) of 21.76 million shares on the Hong Kong Stock Exchange (HKSE), raising a total of HKD 549 million (USD 69.97 million). Company Overview and Core ProductsFounded in 2009, Biocytogen has a pipeline that…
-
Applied Protein Technology Raises Hundreds of Millions in Series B Funding
•
Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision medicine, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by Legend Capital. The funds will allow the company to double down on mass spectrometry multi-omics…
-
Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion
•
Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly care services provider empowered by information technology, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. This follows a Series B round held in December last year, which raised “tens…
-
Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies
•
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly raised RMB59 million (USD8.7 million) in a Series A + financing round. The round was led by Utrust Fund and Baidu Venture, among others. The proceeds will support the research and development of off-the-shelf universal…
-
Menovo Pharmaceutical Plans RMB892m Private Placement to Boost API Production
•
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to raise up to RMB892 million (USD131.6 million) through a private placement. The net proceeds will be used for the creation of an active pharmaceutical ingredients (APIs) and intermediates program with an annual output of 3,760 tons, as well…
-
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
•
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in another financing round. The round was led by CICC ChuanHua Industrial Equity Investment Fund, with other investors including Sunland Fund and Jiangxi State-owned Industry Development Fund. The proceeds will be used for product pipeline layout…
-
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
•
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in another financing round. The round was led by CICC ChuanHua Industrial Equity Investment Fund, with other investors including Sunland Fund and Jiangxi State-owned Industry Development Fund. The proceeds will be used for product pipeline layout…
-
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
•
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed amount of funds in a Series A++ financing round. The round was led by Borchid Capital, with participation from Tongji Fund. The proceeds will be used for the research and development of specialty digital health…
-
Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development
•
Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an angel+ financing round. The round was led by INCE Capital and included contributions from Life Science Park Innovation Investment Fund and Witruth Capital. The proceeds will be used to advance the pre-clinical and clinical development…
-
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
•
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a Series B financing round, led by Innoval Capital. Hefei Industry Investment and Hefei Innovation Investment also participated in the round. The proceeds will be used for research and development, clinical trials, and the construction of…
-
TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion
•
hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round, solely funded by Co-win Ventures. The proceeds will be used for talent recruitment, business expansion in the medical aesthetics and personal care field, and research and development of medical devices.…
-
Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center
•
The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China, last week. The event marked the launch of the Wuxi Intellectual Property (IP) Protection Center. The center already has 52 contracted biomedical projects with a cumulative investment of over RMB30 billion. Biomedical Parks and PlatformsIn…
-
United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion
•
Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing raised RMB12.48 billion (USD1.85 billion) for the firm, bringing its post-listing market capitalization to around RMB100 billion. Company BackgroundFounded in 2011, UIH focuses…
-
Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D
•
China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million) in a Series A financing round. The round was led by Shiseido’s Ziyue Fund, with participation from Hua Fang Investment, CDH Wealth Management, and Holley Pharma. The proceeds will be directed towards investments in technology…
